Cargando…

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver

BACKGROUND: The NO - cGMP system plays a key role in the regulation of sinusoidal tonus and liver blood flow with phosphodiesterase-5 (PDE-5) terminating the dilatory action of cGMP. We, therefore, investigated the effects of PDE-5 inhibitors on hepatic and systemic hemodynamics in rats. METHODS: He...

Descripción completa

Detalles Bibliográficos
Autores principales:	Halverscheid, Leonie, Deibert, Peter, Schmidt, René, Blum, Hubert E, Dunkern, Torsten, Pannen, Benedikt HJ, Kreisel, Wolfgang
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2753560/ https://www.ncbi.nlm.nih.gov/pubmed/19765284 http://dx.doi.org/10.1186/1471-230X-9-69

Ejemplares similares

Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report
por: Bremer, Hinrich C, et al.
Publicado: (2007)

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
por: Kreisel, Wolfgang, et al.
Publicado: (2020)

Beneficial long term effect of a phosphodiesterase-5-inhibitor in cirrhotic portal hypertension: A case report with 8 years follow-up
por: Deibert, Peter, et al.
Publicado: (2018)

Analysis of the nitric oxide-cyclic guanosine monophosphate pathway in experimental liver cirrhosis suggests phosphodiesterase-5 as potential target to treat portal hypertension
por: Schaffner, Denise, et al.
Publicado: (2018)

Bench-to-bedside review: Carbon monoxide – from mitochondrial poisoning to therapeutic use
por: Bauer, Inge, et al.
Publicado: (2009)

Phosphodiesterase type 5 inhibitor to riociguat transition is associated with hemodynamic and symptomatic improvement in pulmonary hypertension
por: Davey, Ryan, et al.
Publicado: (2017)

Close Relationship between Systemic Arterial and Portal Venous Pressure in an Animal Model with Healthy Liver
por: Lazaro, Adhara, et al.
Publicado: (2023)

Potential synergistic effect of phosphodiesterase inhibitors with chemotherapy in lung cancer
por: Domvri, Kalliopi, et al.
Publicado: (2017)

Phosphodiesterase (PDE)-4 Inhibitors and COPD Correlation with Cancer
por: Organtzis, John, et al.
Publicado: (2014)

Evolution of Phosphodiesterase-5 Inhibitors
por: Moon, Du Geon
Publicado: (2015)

Effect of phosphodiesterase inhibitors in the bladder
por: Chughtai, Bilal, et al.
Publicado: (2015)

Cyclic GMP in Liver Cirrhosis—Role in Pathophysiology of Portal Hypertension and Therapeutic Implications
por: Kreisel, Wolfgang, et al.
Publicado: (2021)

Use of sildenafil or other phosphodiesterase inhibitors and risk of melanoma
por: Pottegård, Anton, et al.
Publicado: (2016)

Effect of Phosphodiesterase Inhibitor on Diabetic Nephropathy
por: Kang, Shin-Wook
Publicado: (2012)

Repurposing phosphodiesterase-5 inhibitors as chemoadjuvants
por: Tiwari, Amit K., et al.
Publicado: (2013)

Phosphodiesterase inhibitors as adjunctive therapies for tuberculosis
por: Ahidjo, Bintou Ahmadou, et al.
Publicado: (2016)

New Avenues for Phosphodiesterase Inhibitors in Asthma
por: Matera, Maria Gabriella, et al.
Publicado: (2021)

Could Oral Phosphodiesterase 5 Inhibitors Have a Potential Adjuvant Role in Combating COVID-19 Infection?
por: Mostafa, Taymour
Publicado: (2021)

Methylnaltrexone: the evidence for its use in the management of opioid-induced constipation
por: Deibert, Peter, et al.
Publicado: (2010)

Hemodynamic stress‐induced cardiac remodelling is not modulated by ablation of phosphodiesterase 4D interacting protein
por: Mohamed, Belal A., et al.
Publicado: (2022)

Selective Phosphodiesterase Inhibitors for Psoriasis: Focus on Apremilast
por: Gooderham, Melinda, et al.
Publicado: (2015)

Chemotherapeutic Efficacy of Phosphodiesterase Inhibitors in Chagasic Cardiomyopathy
por: Wen, Jian-jun, et al.
Publicado: (2016)

Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases
por: Li, Heng, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors for colon cancer chemoprevention
por: Islam, Bianca N., et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors and the heart: compound cardioprotection?
por: Hutchings, David Charles, et al.
Publicado: (2018)

Phosphodiesterase-5 inhibitors: Emerging nephroprotective drugs
por: Abassi, Zaid, et al.
Publicado: (2015)

Methylxanthines and Phosphodiesterase Inhibitors in the Treatment of Airways Disease
por: Semple, S J G
Publicado: (1995)

Phosphodiesterase 4 Inhibitors in Allergic Rhinitis/Rhinosinusitis
por: Janosova, Viera, et al.
Publicado: (2020)

Effect and Mechanism of Phosphodiesterase Inhibitors on Trabecular Outflow
por: Kim, Jae Woo, et al.
Publicado: (2019)

Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood‐derived immune cell viability
por: Pletinckx, Katrien, et al.
Publicado: (2019)

Selective Phosphodiesterase 4B Inhibitors: A Review
por: Azam, Mohammed Afzal, et al.
Publicado: (2014)

AB030. Evolution of phosphodiesterase type 5 inhibitors
por: Moon, Du Geon
Publicado: (2016)

The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases
por: Butrous, Ghazwan
Publicado: (2014)

Ciprofloxacin-Induced Antibacterial Activity Is Attenuated by Phosphodiesterase Inhibitors
por: Masadeh, Majed M., et al.
Publicado: (2014)

The Wonders of Phosphodiesterase-5 Inhibitors: A Majestic History
por: Elhwuegi, AS
Publicado: (2016)

Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair
por: Knott, Eric P., et al.
Publicado: (2017)

Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
por: Giorgi, Mauro, et al.
Publicado: (2020)

Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors
por: Joskova, Marta, et al.
Publicado: (2020)

The first‐generation phosphodiesterase 5 inhibitors and their pharmacokinetic issue
por: Zucchi, A., et al.
Publicado: (2019)

COVID-19 and Phosphodiesterase Enzyme Type 5 Inhibitors
por: Al-Kuraishy, Hayder M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_v1lmmhl26etlf0j0qt7vun1bd5